Published in Blood Weekly, July 12th, 2001
The report, issued in the European Journal of Haemotology, by researchers at Humboldt University in Germany, revealed studies of bone marrow microvessel density (MVD) counts obtained from myeloma patients after receiving low- or high-dose chemotherapy and autologous stem cell transplants show angiogenesis markers can predict outcomes.
With the use of immunohistochemical staining for CD34, O. Sezer and coworkers counted the average...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Blood Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.